Avacta Group plc (LSE:AVCT) has shared preliminary findings from its Phase 1b clinical trial evaluating Faridoxorubicin in patients with salivary gland cancer. Full results will be unveiled on 17 December 2025. The early data represent an important milestone for Avacta as it continues to advance its peptide drug conjugate (PDC) platform, aimed at delivering more targeted cancer treatments with improved safety and efficacy. This progress strengthens the company’s positioning within the field of next-generation oncology therapeutics.
Despite the encouraging scientific developments, Avacta’s broader outlook remains constrained by significant financial pressures. Heavy dependence on external funding, a lack of profitability, and valuation challenges continue to weigh on sentiment, even as technical indicators and recent corporate updates offer pockets of optimism.
More about Avacta Group plc
Avacta Group plc is a clinical-stage life sciences company developing innovative oncology treatments using its proprietary pre|CISION® platform. The technology is designed to create peptide drug conjugates (PDCs) that activate selectively within tumour environments, enhancing drug effectiveness while minimising systemic toxicity and side effects.









